Science Corporation Launches PRIMA Retinal Implant in Europe

What Happened

Science Corporation has officially announced the European commercial launch of its PRIMA retinal implant system. This milestone follows the successful acquisition of a CE mark under the European Union Medical Device Regulation, granted by the regulatory body DEKRA. With this certification, the device is now authorized for commercial distribution across 30 European countries. The launch represents a transition from clinical research to real-world application for a technology designed to address the profound vision loss associated with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The company has begun the process of country-specific reimbursement applications and is currently activating clinical sites across the continent. Germany has been identified as the initial market for the first commercial implantations. This rollout follows a robust period of clinical validation, including a multicenter study published in the New England Journal of Medicine, which provided the clinical evidence necessary to secure regulatory approval.

Key Details

The PRIMA system is a subretinal photovoltaic implant that functions as a brain-computer interface (BCI). Unlike traditional implants that might rely on external cameras mounted on glasses, the PRIMA system uses a specialized pair of glasses that project near-infrared light directly onto the subretinal device. The implant then converts this light into electrical stimulation, which is transmitted to the retinal cells, effectively bypassing the damaged areas of the macula.

The clinical trial, which served as the cornerstone for the CE mark, involved 38 patients across 17 clinical sites in five countries. The results demonstrated clear efficacy in restoring functional central vision. Key findings from the study included:

• A mean improvement of 25.5 ETDRS letters, which is equivalent to more than five lines on a standard visual acuity chart.
• 84% of participants reported the ability to read letters, numbers, and words following the implantation.
• 80% of participants achieved improvements of at least 0.2 logMAR (approximately 10 ETDRS letters) at the 12-month mark.

The device is designed with an ultra-thin profile, allowing it to be positioned beneath the atrophic macula without interfering with the patient's residual natural vision. Furthermore, the system includes a zoom function, providing patients with the ability to magnify text, which is a critical feature for those attempting to regain reading capabilities.

Context

Age-related macular degeneration is a leading cause of vision loss globally, particularly among the elderly. Geographic atrophy, an advanced form of dry AMD, involves the progressive degeneration of the retinal pigment epithelium and photoreceptors in the macula—the part of the eye responsible for sharp, central vision. For patients with GA, the loss of central vision is often irreversible, leading to a total inability to read, recognize faces, or perform tasks requiring fine detail. Historically, there have been few, if any, viable treatments capable of restoring this level of functional vision once the damage has occurred.

Science Corporation’s development of the PRIMA system represents a shift in how the medical community approaches retinal degeneration. By leveraging BCI technology, the company is not merely attempting to slow the progression of the disease but is actively working to restore a lost sensory function. The device's approval in Europe suggests a growing regulatory acceptance of BCI-based implants as a legitimate therapeutic pathway for neuro-ophthalmological conditions.

Why It Matters

The launch of PRIMA is significant for several reasons. First, it provides a tangible solution for a patient population that previously had no options for vision restoration. The ability to read, even if through a prosthetic interface, represents a major increase in independence and quality of life for those suffering from advanced AMD.

Second, the success of the PRIMA system highlights the potential of BCI technology in fields beyond motor control. While much of the public discourse around BCIs has focused on neural implants for paralysis, the PRIMA system demonstrates that these interfaces can be highly effective in sensory restoration. The fact that the device has received a CE mark validates the safety and efficacy of this specific BCI application.

Finally, the clinical data underscores the precision of the technology. Achieving a 25.5-letter improvement on the ETDRS chart is a statistically significant outcome that suggests the device is providing high-resolution stimulation to the retina, allowing for the recognition of complex forms like letters and numbers, rather than just simple light detection.

Bottom Line

Science Corporation has successfully moved the PRIMA retinal implant from the laboratory to the European market, offering a new hope for patients with geographic atrophy. While the commercial rollout is currently focused on Europe, the company remains actively engaged with the U.S. Food and Drug Administration (FDA) to bring the technology to the United States. Having already secured both Breakthrough Device and Humanitarian Use Device designations from the FDA, the company is well-positioned for future expansion. As the first commercial implantations begin in Germany, the medical community will be closely watching the long-term, real-world performance of this BCI-based vision system.

Pneumetron